About Kynurenine--oxoglutarate transaminase 3
Kynurenine--oxoglutarate transaminase 3 (KYAT3) is a protein
from Homo sapiens identified by UniProt accession
Q6YP21, 454 residues long.
MolForge cross-references it against 0 known binders and
54 disease associations.
Target properties
| Protein name | Kynurenine--oxoglutarate transaminase 3 |
| UniProt accession | Q6YP21 |
| Gene | KYAT3 |
| Organism | Homo sapiens |
| Length | 454 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (54)
Diseases linked to this target (Open Targets).
- serum metabolite measurement · score 0.18
- urinary metabolite measurement · score 0.16
- blood urea nitrogen measurement · score 0.13
- pulse pressure measurement · score 0.10
- breast cancer · score 0.07
- systolic blood pressure · score 0.07
- platelet crit · score 0.07
- appendicular lean mass · score 0.06
- creatinine measurement · score 0.05
- diastolic blood pressure · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6YP21-F1 | alphafold | PREDICTED | 91.31 | — |
Amino-acid sequence (454 residues)
MFLAQRSLCS LSGRAKFLKT ISSSKILGFS TSAKMSLKFT NAKRIEGLDS NVWIEFTKLA ADPSVVNLGQ GFPDISPPTY VKEELSKIAA IDSLNQYTRG FGHPSLVKAL SYLYEKLYQK QIDSNKEILV TVGAYGSLFN TIQALIDEGD EVILIVPFYD CYEPMVRMAG ATPVFIPLRS KPVYGKRWSS SDWTLDPQEL ESKFNSKTKA IILNTPHNPL GKVYNREELQ VIADLCIKYD TLCISDEVYE WLVYSGNKHL KIATFPGMWE RTITIGSAGK TFSVTGWKLG WSIGPNHLIK HLQTVQQNTI YTCATPLQEA LAQAFWIDIK RMDDPECYFN SLPKELEVKR DRMVRLLESV GLKPIVPDGG YFIIADVSLL DPDLSDMKNN EPYDYKFVKW MTKHKKLSAI PVSAFCNSET KSQFEKFVRF CFIKKDSTLD AAEEIIKAWS VQKS
Explore Kynurenine--oxoglutarate transaminase 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets